UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 15, 2018

| | | ALEXION PHARMACEUTICALS | S, INC. | | | | | | | |
|--|---|--|--|--|--|--|--|--|--|--|
| (Exact name of registrant as specified in its charter) | | | | | | | | | | |
| Delaware | | 000-27756 | 13-3648318 | | | | | | | |
| (State or other jurisdiction of incorporation or organization) | | (Commission File Number) | (I.R.S. Employer Identification No.) | | | | | | | |
| | <u>121</u> | <u>Seaport Boulevard, Boston, Massach</u> | nusetts 02210 | | | | | | | |
| | (Ad | dress of Principal Executive Offices) | (Zip Code) | | | | | | | |
| | Registrant' | s telephone number, including area c | rode: (475) 230-2596 | | | | | | | |
| | | Not Applicable | | | | | | | | |
| | | (Former address if changed since las | t report) | | | | | | | |
| | | orm 8-K filing is intended to simultane e General Instruction A.2. below): | eously satisfy the filing obligation of the registrant | | | | | | | |
| | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | | | | | | | | | |
| | Soliciting material pursuant to F (17 CFR 240.14a-12) | Rule 14a-12 under the Exchange Act | | | | | | | | |
| | Pre-commencement communication (17 CFR 240.14d-2(b)) | ations pursuant to Rule 14d-2(b) under | the Exchange Act | | | | | | | |
| | Pre-commencement communication (17 CFR 240.13e-4(c)) | ations pursuant to Rule 13e-4(c) under | the Exchange Act | | | | | | | |
| | | trant is an emerging growth company a 2b-2 of the Securities Exchange Act o | as defined in Rule 405 of the Securities Act of f 1934 (§240.12b-2 of this chapter). | | | | | | | |
| | Emerging growth company | | | | | | | | | |
| | | | ted not to use the extended transition period for uant to Section 13(a) of the Exchange Act. □ | | | | | | | |

Item 7.01 Regulation FD Disclosure.

On November 15, 2018, a complaint was filed against Alexion Pharmaceuticals, Inc. by Chugai Pharmaceutical Co., Ltd. in the U.S. District Court for Delaware alleging that ALXN1210 infringes a U.S. patent held by Chugai. We believe that we have valid legal defenses against Chugai's infringement claims. Accordingly, we intend to oppose these claims and intend to proceed with our business plans for ALXN1210.

This Form 8-K contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, including statements related to the Chugai litigation and our business plans for ALXN1210. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ materially from those forward-looking statements, including uncertainties related to our legal proceedings and other risks set forth from time to time in Alexion's filings with the SEC, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2018. Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

Signature

| Pursu | ant to the requirement | s of the Securities | Exchange Act o | f 1934, the | registrant has | duly caused t | his report to b | be signed | on its | behalf |
|----------------|------------------------|---------------------|----------------|-------------|----------------|---------------|-----------------|-----------|--------|--------|
| by the undersi | igned hereunto duly au | thorized. | | | | | | | | |

Date: November 16, 2018 ALEXION PHARMACEUTICALS, INC.

By: <u>/s/ Douglas Barry</u>

Name: Douglas Barry

Title: Vice President, Corporate Law